Andrew A. Wilson, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, University of Texas Southwestern Medical School




I am a pulmonary and critical care clinician-scientist with a long-standing focus on regenerative medicine and stem cell biology. My goal is to advance understanding of and treatment for genetic causes of chronic obstructive pulmonary disease (COPD) and the most common genetic cause of COPD, alpha-1 antitrypsin deficiency (AATD). To accomplish this goal, I have established an integrated clinical and research program here at BU and BMC that includes the following components: 1) The Alpha-1 Center which I direct and co-founded with Dr. Darrell Kotton has become a nationally recognized center of excellence for the care of AATD patients and their families; 2) Patient stem cell repositories: I have overseen the creation of and direct two large stem cell repositories, housed at the CReM. First, we house the world’s largest AATD patient-specific induced pluripotent stem cell (iPSC) repository, comprised of iPSCs and reprogrammable blood samples from over 100 AATD patients linked to phenotypic data including imaging, pulmonary function, and liver biopsy results. Second, in collaboration with the Framingham Heart Study (FHS) and Vasan Ramachandran, the CReM now houses the FHS iPSC Repository that includes iPSCs and reprogrammable blood samples from >6500 highly phenotyped participants in the FHS; 3) Clinical-epidemological AATD Research: Under my direction as site PI, BU is one three sites in the country funded by the Alpha-1 Foundation to recruit 100 AATD subjects to undergo liver biopsy, detailed phenotyping, and 5 years of follow-up to define the prevalence of, risk factors for, and non-invasive biomarkers associated with AATD-associated liver disease; 4) Translational bench research: my lab in the CReM is focused on the application of patient-derived iPSCs to study AATD and COPD.

The 4 core areas of my research are: I) to confirm the clinical significance of the iPSC platform to model in vivo patient biology and demonstrate its potential for testing potential therapeutic agents; II) to better understand the genetic factors and mechanistic drivers that predispose subsets of AATD patients to develop clinical disease; III) to elucidate the mechanistic contribution of putative COPD susceptibility genes to lung disease pathogenesis; and IV) to develop gene or cell-based therapies for AATD.


Research interests include:
-Alpha-1 antitrypsin deficiency
-COPD pathogenesis
-Gene therapy
-Pluripotent stem cells

Clinical interests include:
-Alpha-1 antitrypsin deficiency

Investigator
Framingham Heart Study


Member
Boston University
Pulmonary Center


Member
Boston University
Center for Regenerative Medicine


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences




Thyroid Hormone Signaling in Human Hepatocytes
04/01/2019 - 01/31/2023 (Subcontract PI)
Weill Medical College of Cornell University NIH NIDDK
5R01DK117940-03

Novel Gene and Stem Cell Therapy for Type 1 Diabetes
08/01/2019 - 05/31/2022 (Subcontract PI)
Medical University of South Carolina NIH NIDDK
5R01DK120394-03

Defining the alveolar epithelial response to SARS-CoV-2 and additional risk of cigarette smoke or e-cig vapor exposure
07/01/2020 - 06/30/2021 (PI)
American Lung Association


Functional characterization of risk modifier gene MAN1B1 in patient-derived hepatocytes
07/01/2018 - 06/30/2021 (PI)
Alpha 1 Foundation


A National iPS cell network with deep phenotyping for translational research
09/15/2016 - 06/30/2021 (Multi-PI)
PI: Andrew A. Wilson, MD
NIH/National Center for Advancing Translational Sciences
5U01TR001810-05

Personalized therapy for AATD-associated liver disease via IPS modeling
07/01/2015 - 06/30/2021 (PI)
NIH/National Diabetes & Digestive & Kidney Diseases
5R01DK101501-05

Application of Isogenic CRISPR-corrected Patient iPSCs to Determine Whether ZAAT-Induced Gain of Function Toxicity Renders MZ or ZZ Lung Epithelium Susceptible to Cigarette Smoke Injury
05/09/2019 - 05/08/2021 (PI)
Grifols Inc


Base Editing in Patient-derived Pluripotent Stem Cells for Disease Modeling and Therapeutic Development
04/12/2019 - 04/12/2021 (PI)
Beam Therapeutics, Inc.


Clinical Resource Center Registry to Alpha-1 Foundation transfer award
04/15/2020 - 12/31/2020 (PI)
Alpha 1 Foundation


Contribution of Gain of Function Toxicity to AATD Lung Disease Pathogenesis
10/01/2018 - 09/30/2019 (PI)
Alpha 1 Foundation


Showing 10 of 22 results. Show All Results

ALPHA-1 Antitrypsin Deficiency Adult Clinical
01/01/2015 - 07/23/2020 (PI)
Alpha-1 Foundation

Alpha-1 Antitrypsin Deficiency Adult Clinical and Genetic Linkage Study
01/01/2015 - 07/23/2020 (PI)
St. Louis University Alpha-1 Foundation


Title


Yr Title Project-Sub Proj Pubs
2021 Thyroid Hormone Signaling in Human Hepatocytes 5R01DK117940-03
2020 Thyroid Hormone Signaling in Human Hepatocytes 5R01DK117940-02
2020 A National iPS Cell Network with Deep Phenotyping for Translational Research 5U01TR001810-05 12
2019 Thyroid Hormone Signaling in Human Hepatocytes 1R01DK117940-01A1
2019 A National iPS Cell Network with Deep Phenotyping for Translational Research 5U01TR001810-04 12
2019 Personalized therapy for AATD-associated liver disease via IPS modeling 5R01DK101501-05 3
2018 A National iPS Cell Network with Deep Phenotyping for Translational Research 3U01TR001810-03S1 12
2018 A National iPS Cell Network with Deep Phenotyping for Translational Research 5U01TR001810-03 12
2018 Personalized therapy for AATD-associated liver disease via IPS modeling 5R01DK101501-04 3
2017 A National iPS Cell Network with Deep Phenotyping for Translational Research 5U01TR001810-02 12
Showing 10 of 19 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Werder RB, Kaserman JE, Packer MS, Lindstrom-Vautrin J, Villacorta-Martin C, Young LE, Aratyn-Schaus Y, Gregoire F, Wilson AA. Adenine base editing reduces misfolded protein accumulation and toxicity in alpha-1 antitrypsin deficient patient iPSC-hepatocytes. Mol Ther. 2021 Jul 02.View Related Profiles. PMID: 34217893
     
  2. Tilston-Lunel A, Mazzilli S, Kingston NM, Szymaniak AD, Hicks-Berthet J, Kern JG, Abo K, Reid ME, Perdomo C, Wilson AA, Spira A, Beane J, Varelas X. Aberrant epithelial polarity cues drive the development of precancerous airway lesions. Proc Natl Acad Sci U S A. 2021 May 04; 118(18).View Related Profiles. PMID: 33903236; PMCID: PMC8106308; DOI: 10.1073/pnas.2019282118;
     
  3. Hekman RM, Hume AJ, Goel RK, Abo KM, Huang J, Blum BC, Werder RB, Suder EL, Paul I, Phanse S, Youssef A, Alysandratos KD, Padhorny D, Ojha S, Mora-Martin A, Kretov D, Ash PEA, Verma M, Zhao J, Patten JJ, Villacorta-Martin C, Bolzan D, Perea-Resa C, Bullitt E, Hinds A, Tilston-Lunel A, Varelas X, Farhangmehr S, Braunschweig U, Kwan JH, McComb M, Basu A, Saeed M, Perissi V, Burks EJ, Layne MD, Connor JH, Davey R, Cheng JX, Wolozin BL, Blencowe BJ, Wuchty S, Lyons SM, Kozakov D, Cifuentes D, Blower M, Kotton DN, Wilson AA, Mühlberger E, Emili A. Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2. Mol Cell. 2021 Jan 07; 81(1):212.View Related Profiles. PMID: 33417854; PMCID: PMC7831449; DOI: 10.1016/j.molcel.2020.12.028;
     
  4. Hekman RM, Hume AJ, Goel RK, Abo KM, Huang J, Blum BC, Werder RB, Suder EL, Paul I, Phanse S, Youssef A, Alysandratos KD, Padhorny D, Ojha S, Mora-Martin A, Kretov D, Ash PEA, Verma M, Zhao J, Patten JJ, Villacorta-Martin C, Bolzan D, Perea-Resa C, Bullitt E, Hinds A, Tilston-Lunel A, Varelas X, Farhangmehr S, Braunschweig U, Kwan JH, McComb M, Basu A, Saeed M, Perissi V, Burks EJ, Layne MD, Connor JH, Davey R, Cheng JX, Wolozin BL, Blencowe BJ, Wuchty S, Lyons SM, Kozakov D, Cifuentes D, Blower M, Kotton DN, Wilson AA, Mühlberger E, Emili A. Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2. Mol Cell. 2020 12 17; 80(6):1104-1122.e9.View Related Profiles. PMID: 33259812; PMCID: PMC7674017; DOI: 10.1016/j.molcel.2020.11.028;
     
  5. Huang J, Hume AJ, Abo KM, Werder RB, Villacorta-Martin C, Alysandratos KD, Beermann ML, Simone-Roach C, Lindstrom-Vautrin J, Olejnik J, Suder EL, Bullitt E, Hinds A, Sharma A, Bosmann M, Wang R, Hawkins F, Burks EJ, Saeed M, Wilson AA, Mühlberger E, Kotton DN. SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. Cell Stem Cell. 2020 12 03; 27(6):962-973.e7.View Related Profiles. PMID: 32979316; PMCID: PMC7500949; DOI: 10.1016/j.stem.2020.09.013;
     
  6. Giadone RM, Liberti DC, Matte TM, Rosarda JD, Torres-Arancivia C, Ghosh S, Diedrich JK, Pankow S, Skvir N, Jean JC, Yates JR, Wilson AA, Connors LH, Kotton DN, Wiseman RL, Murphy GJ. Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease. Stem Cell Reports. 2020 08 11; 15(2):515-528.View Related Profiles. PMID: 32735824; PMCID: PMC7419739; DOI: 10.1016/j.stemcr.2020.07.003;
     
  7. Kaserman JE, Hurley K, Dodge M, Villacorta-Martin C, Vedaie M, Jean JC, Liberti DC, James MF, Higgins MI, Lee NJ, Washko GR, San Jose Estepar R, Teckman J, Kotton DN, Wilson AA. A Highly Phenotyped Open Access Repository of Alpha-1 Antitrypsin Deficiency Pluripotent Stem Cells. Stem Cell Reports. 2020 07 14; 15(1):242-255.View Related Profiles. PMID: 32619491; PMCID: PMC7363960; DOI: 10.1016/j.stemcr.2020.06.006;
     
  8. Huang J, Hume AJ, Abo KM, Werder RB, Villacorta-Martin C, Alysandratos KD, Beermann ML, Simone-Roach C, Olejnik J, Suder EL, Bullitt E, Hinds A, Sharma A, Bosmann M, Wang R, Hawkins F, Burks EJ, Saeed M, Wilson AA, Mühlberger E, Kotton DN. SARS-CoV-2 Infection of Pluripotent Stem Cell-derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. bioRxiv. 2020 Jun 30.View Related Profiles. PMID: 32637964; PMCID: PMC7337394; DOI: 10.1101/2020.06.30.175695;
     
  9. Abo KM, Ma L, Matte T, Huang J, Alysandratos KD, Werder RB, Mithal A, Beermann ML, Lindstrom-Vautrin J, Mostoslavsky G, Ikonomou L, Kotton DN, Hawkins F, Wilson A, Villacorta-Martin C. Human iPSC-derived alveolar and airway epithelial cells can be cultured at air-liquid interface and express SARS-CoV-2 host factors. bioRxiv. 2020 Jun 04.View Related Profiles. PMID: 32577635; PMCID: PMC7302183; DOI: 10.1101/2020.06.03.132639;
     
  10. Hurley K, Ding J, Villacorta-Martin C, Herriges MJ, Jacob A, Vedaie M, Alysandratos KD, Sun YL, Lin C, Werder RB, Huang J, Wilson AA, Mithal A, Mostoslavsky G, Oglesby I, Caballero IS, Guttentag SH, Ahangari F, Kaminski N, Rodriguez-Fraticelli A, Camargo F, Bar-Joseph Z, Kotton DN. Reconstructed Single-Cell Fate Trajectories Define Lineage Plasticity Windows during Differentiation of Human PSC-Derived Distal Lung Progenitors. Cell Stem Cell. 2020 04 02; 26(4):593-608.e8.View Related Profiles. PMID: 32004478; PMCID: PMC7469703; DOI: 10.1016/j.stem.2019.12.009;
     
Showing 10 of 30 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 30 publications over 13 distinct years, with a maximum of 7 publications in 2020

YearPublications
19931
20083
20091
20121
20132
20141
20152
20161
20173
20184
20191
20207
20213
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

alpha-1 antitrypsin
gene therapy
Contact for Mentoring:

72 E. Concord St Housman (R)
Boston MA 02118
Google Map


Wilson's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department